Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sir Mortimer B. Davis - Jewish General Hospital
Age
18–100
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Resident of Canada
Male sex
Age 18 years or older
Progressive (symptoms, conventional imaging, PSA, bone scan, FCH PET/CT or other) castration-resistant prostate cancer in the judgment of the treating physician without change in systemic anti-neoplastic therapy since documented progression
Six or greater bone metastases robustly-avid on recent (4 weeks) MDP or NaF scintigraphy
Recently failed (within 3 months) or failing novel androgen receptor pathway inhibitors (abiraterone + prednisone or enzalutamide) with intention of continuing the drug for at least 7 months OR minimum 14 day washout period from either agent prior to study enrollment
No known visceral metastases or adenopathy greater than 3 cm short axis on conventional imaging
Not received docetaxel for castration-resistant disease
ECOG performance status 0 - 2, inclusive
Life expectancy of greater than 6 months
Serum testosterone less than or equal to 50 ng/dl
Hemoglobin greater than or equal to 100 g/L with no blood transfusions or EPO in preceding 3 weeks
Neutrophils greater than or equal to 1.5 x109/L
Platelets greater than or equal to 100 x109/L
No prior hemi-body radiotherapy
No impending or established spinal cord compression
No unmanageable fecal incontinence
Patient has good IV access
Able to understand and provide written informed consent
You may not be if
Planned change in systemic anti-neoplastic therapy during the approximately 7 month trial
Unable to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 30 minutes with the arms above the head and tolerating intravenous cannulation for injection of the study drug.
Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)
Patients who exceed the safe weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (70 cm diameter)
Patients who are claustrophobic
Clareo Health | Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
